|
Research InterestsAssociate Professor Tom Shakespeare | | (Position Details) | | Phone 02 66565125 | | Email | | Qualifications MBBS, Masters Public Health |
| | | School/Unit |
| Rural Clinical School | |
| | Broad Research Areas | |
|
Cancer
Health Services Research
Medical Education
Medical Radiation Physics
Clinical Research
| |
| | | | Specific Research Keywords | |
| Radiation Oncology
Prostate Cancer
Decision Making
Prostate Cancer
Breast Cancer
| |
| | | | Research Interests | |
|
Treatment of prostate cancer using hormone therapy and radiotherapy, including new techniques such as intensity-modulated radiotherapy. Includes measures of efficacy (PSA response, survival), side-effects and QOL. Also research including patient involvement in decision-making, and decision-regret. Treatment of breast cancer including outcomes following intensity modulated radiotherapy. Also research of patient involvement in decision-making, and decision-regret. Education of oncologists including evaluation of performance using peer-review audit and adherence to State protocols. Various research projects of radiotherapy techniques including intensity-modulated radiotherapy, image guidance, volumatric arc therapy etc.
| |
| | | | ILP Research Interests (Will supervise ILP students) |
| Audit
Breast Cancer
Continuing Education
Decision Making
Oncology
Prostate Cancer
| |
| | | | Teaching Interests | |
| Clinical oncology | |
| | | | Society Memberships & Professional Activities | |
| NSW Cancer Institute Urology Oncology Group
Faculty of Radiation Oncology Genitourinary Oncology Group (FROGG)
Post-Fellowship Education Committee, RANZCR
NSW Cancer Institute Clinical Services Advisory Committee
NSW Directors of Radiation Oncology Committee
Royal Australian and New Zealand College of Radiologists (RANZCR)
European Society for Therapeutic Radiology and Oncology (ESTRO)
American Society for Therapeutic Radiology and Oncology (ASTRO)
American Society of Clinical Oncology (ASCO)
Singapore Society of Oncology (SSO)
Singapore Radiological Society (SRS)
Academy of Medicine, Singapore (AMS) | |
| | | | Funding Sources | |
| RNSH Medical and Ancillary Trust Fund Grant 1996
Value: $2500
Awarded July 1996 for the project: Intracranial epithelioid haemangio-endothelioma arising at site of resection of previously excised atypical meningioma
RNSH Medical and Ancillary Trust Fund Grant 1997
Value: $3000
Awarded July 1997 for the project: Difficulties using the Franco-Italian Glossary in assessing toxicity of cervical cancer treatment.
NSW Cancer Institute
Value $130,000
Grant for NSW Cancer Institute Fellow, 2006
Value $74,460
Technology Enhancement Grant for Nasendoscope units 2006
Value $120,000
PI for Prostate Cancer MDT Grant
Value $80,000
Supervisor for Lung Cancer MDT Grant
Value $10,000
PI for Cancer Services accreditation pilot Grant
Cancer Australia
Value: $2,000,000
Lead for North Coast Area Health Service to develop a cancer network across 3 AHSs.
NMRC
Value: $800,000
Collaborator for a grant for a research project titled: The use of long wave ultrasound to upregulate endogenous bone morphogenetic proteins (BMP) and angiogenic factors (AF) in normal and irradiated bone.
NHG Research Grants
Principal Investigator for $40,000 grant for the National University Hospital Cancer Registry.
Collaborator for $78,000 grant by NHG for a lung cancer research database
Collaborator in $20,000 for unmet cancer needs research
Collaborator in $48,297 for valproic acid and radiation in the lytic induction of EBV in NPC. | |
| | | | Key works/Publications | |
| 1. Shakespeare TP, Stevens MJ. Unilateral facial pain and lung cancer. Australas Radiol. 1996: 40: 45-46.
2. Shakespeare TP, Slancar MM, Mallik AR, Bell DR. CSF dissemination of a benign choroid plexus papilloma. Internal Medicine Journal (Aust NZ J Med). 1997: 27: 597-598. IF 1.518.
3. Shakespeare TP. Dissection of regional lymph nodes in cutaneous melanoma [letter]. Lancet. 1998: 351: 1885. IF 23.878.
4. Shakespeare TP, Ferrier AJ, Holecek MJ, Jagavkar R, Stevens MJ. Difficulties using the Franco-Italian Glossary in assessing toxicity of cervical cancer treatment. Int J Gynecol Cancer. 1998: 8: 51-55. IF 1.427.
5. Shakespeare TP, Holecek MJ. The importance of using confidence intervals when reporting results of studies in abstract form [Letter]. Int J Gynecol Cancer. 1998: 8: 165. IF 1.427.
6. Shakespeare TP, Holecek MJ. Defining involved field (IF) radiotherapy in Hodgkin’s disease [letter]. Australas Radiol. 1998: 42: 172-173.
7. Fryer JA, Biggs MT, Katz IA, Brazier DH, Shakespeare TP. Intracranial epithelioid haemangioendothelioma arising at site of resection of previously excised atypical meningioma. Pathology. 1998: 30: 95-99. IF 1.471.
8. Shakespeare TP, Holecek MJ. Should we be using confidence intervals when reporting results of oncology studies? [letter]. Int J Radiat Oncol Biol Phys. 1998: 41: 971-972. IF 4.556.
9. Jagavkar RS, Shakespeare TP, Stevens MJ. Endometrial adenosarcoma with adjuvant tamoxifen therapy for primary breast carcinoma. Australas Radiol. 1998: 42: 157-158.
10. Shakespeare TP, Bourke RC. Systematic review of trials comparing antibiotic with placebo for acute cough in adults. Too few subjects were studied for useful conclusions to be drawn [letter]. BMJ. 1998: 317: 1014-5. IF 9.052.
11. Delaney G, Hui A, Berry M, Fowler A, Kneebone A, Barton M, Shakespeare T, Campbell G, Della-Fiorentina S, Brown K. Don't block the new kids [letter]. Australas Radiol. 43(4): 562, 1999 Nov.
12. Shakespeare TP, Gebski VJ, Veness MJ, Simes J. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Lancet. 2001: 357: 1349–53. IF 23.878.
13. Shakespeare TP. Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. Comment. Curr News Med. 2001: 1:6.
14. Ong KJ, Back MF, Lu JJ, Shakespeare TS, Wynne CJ. Cultural attitudes to cancer management in traditional south-east Asian patients. Australas Radiol 2002; 46(4): 370-374.
15. Shakespeare TP, Dwyer MK, Mukherjee R, Yeghiaian-Alvandi R, Gebski VJ. Estimating risks of radiotherapy complications as part of informed consent: the high degree of variability between radiation oncologists may be related to experience. Int J Radiat Oncol Biol Phys. 2002; 54(3): 647-653. Editorial: Trotti A, Chin LJ. Adverse effects: a Pandora’s box for oncology pp 642-646. IF 4.556.
16. Chua MST, Veness MJ, Morgan G, ShakespeareTP, Hehir A, Gebski V, Cakir B, Tiver KW. Parotid lymph-node metastases from cutaneous squamous-cell carcinomas: Treatment outcome and prognostic factors following surgery and adjuvant radiotherapy. Australas Radiol 2002; 46(2): 174-179.
17. Shakespeare TP. Palliation of esophageal cancer: there is no clear winner [Letter]. Int J Radiat Oncol Biol Phys. 2003; 55(3): 849-850. IF 4.556.
18. Shakespeare TP, Lu JJ, Back MF, Liang S, Rahul RK, Wynne CJ. Patient preference for radiotherapy fractionation schedule in the palliation of painful bone metastases. J Clin Oncol 2003; 21(11): 2156-2162. IF 11.810.
19. Mukherjee RK, Back MF, Lu JJ, Shakespeare TP, Wynne CJ. Hiding in the bunker: Challenges for a radiation oncology department operating in the Severe Acute Respiratory Syndrome outbreak. Australas Radiol. 2003 Jun;47(2):143-5.
20. Yoon KH, Wong A, Shakespeare TP, Sivalingam P. High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus 2003; 12(2): 112-116. IF 2.400.
21. Back M, Shanmugan P, Shakespeare TP, Wynne CJ. Introducing the Intergroup 0016 protocol of adjuvant chemoradiotherapy in gastric cancer into clinical practice. Clin Oncol (RCR) 2003; 15:378-382. IF 1.288.
22. Shakespeare TP, Back MF, Lu JJ, Wynne CJ, Bloomfield L. Design of an internationally accredited radiation oncology training program incorporating novel educational models. Int J Radiat Oncol Biol Phys 2004; 59(4): 1157-1162. IF 4.556.
23. Balubarsaringam M, Lu JJ, Chong J, Tan TKL, Shakespeare TP. Tailoring distant metastatic imaging for patients with clinically localized undifferentiated nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2004; 58 (3): 688-693. IF 4.556.
24. Lu JJ, Shakespeare T, Goh BC, Chua ET, Back M, Mukherjee R, Wynne C, Kim Tan KSL. Adjuvant high-dose rate brachytherapy after chemoradiation for treatment of early T-stage nasopharyngeal carcinoma. Am J Clin Oncol 2004; 27(2): 132-13. IF 1.615.
25. Shakespeare TP, Mukherjee RK, Lu JJ, Wynne CJ, Kumar MB, Back MF. A comparison of RANZCR and Singapore-designed Radiation Oncology practice audit instruments: how does reproducibility affect future approaches to revalidation? Australas Radiol 2004; 48: 195-203.
26. Lu JJ, Shakespeare TP, Tan TKL, Goh BC, Cooper JS. Adjuvant Fractionated High-Dose-Rate Intracavitary Brachytherapy after External Beam Radiotherapy in T1 and T2 Nasopharyngeal Carcinoma. Head Neck 2004; 26: 389-395. IF 1.975.
27. Macbeth F, Stephens R, Abratt RP, Arriagada R, Ball D, Bezjak A, Billingham L, Crowley J, O’Brien M, Shakespeare T, Thompson E, van Meerbeeck J. An open letter to all members of the IASLC (Editorial). Lung Cancer 2004; 45(1): 119-120. IF 3.172.
28. Chung HT, Shakespeare TP, Wynne CJ, Mukherjee RK, Back MF. Evaluation of a radiotherapy protocol based on INT0116 for completely resected gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2004; 59(5): 1446-1453. IF 4.556.
29. Lim KH, Lu JJ, Wynne CJ, Back MF, Mukherjee R, Razvi K, Shakespeare TP. A Study of Complications arising from Different Methods of Analgesia used in Brachytherapy for Cervical Cancer. Am J Clin Oncol 2004; 27(5): 449-51. IF 1.615.
30. Tang JI, Shakespeare TP, Zhang XJ, Lu JJ, Liang S, Wynne CJ, Mukherjee RK, Back MF. Patient satisfaction with doctor-patient interaction in a radiotherapy center during the severe acute respiratory syndrome outbreak. Australas Radiol 2005; 49:304-311.
31. Tang JI, Back M, Shakespeare TP, Lu JJ, Mukherjee RK, Wynne C, Liang S. Interpreting the improved outcome of patients with central nervous system metastases managed in clinical trials compared with standard hospital practice. Australas Radiol. 2005 Oct;49(5):390-5.
32. Shakespeare TP, Thiagarajan A, Gebski VJ. Evaluation of the quality of radiotherapy randomized trials for painful bone metastases: Implications for future research design and reporting. Cancer 2005; 103(9): 1976-1981. IF 4.8.
33. Lu JJ, Shakespeare TP, Thiagarajan A, Zhang XJ, Tan LLS. Prospective Phase II Trial of Concomitant Boost Radiotherapy For Stage II Nasopharyngeal Carcinoma: An Evaluation of Response and Toxicity. Laryngoscope 2005;115(5):806-810. IF 1.617.
34. Shakespeare TP, Mukherjee RK, Back MF, Wynne CJ, Kumar MB, Zhang, Lu JJ. Audit with feedback (AWF) as a CME tool for radiation oncologists (ROs): evaluation of efficacy, perception, and cost-effectiveness. J Cancer Educ 2005; 20:216-221. IF 0.672.
35. Shakespeare TP, Back MF, Lu JJ, Mukherjee RK, Lee KM. External audit of clinical practice and medical decision-making in a new Asian oncology center: results and implications for developing and developed nations. Int J Radiation Oncology Biology Physics 2006; 64(3): 941-947. IF 4.556.
36. Shakespeare TP, Lim K, Lee KM, Lu JJ, Mukherjee R, Back MF. Phase II study of the American Brachytherapy Society guidelines for the use of high dose rate (HDR) brachytherapy in the treatment of cervical carcinoma: is 45-50.4Gy radiochemotherapy plus 31.8Gy in 6 fractions HDR brachytherapy tolerable? Int J Gynecol Cancer 2006; 16: 277-282. IF 1.427.
37. Shakespeare TP, Gebski VJ, Thiagarajan A, Jay Lu J. Development of a spreadsheet for the calculation of new tools to improve the reporting of the results of medical research. Med Inform Internet Med 2006; 31(2): 121-127. IF 0.419.
38. Wong ASC, Soo RA, Lu LL, Loh KS, Tan KS, Hsieh WS, Shakespeare TP, Chua ET, Lim HL, and Goh BC. Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma. Ann Onc 2006; 17:1152-7. IF 4.319.
39. Leong CN, Shakespeare TP, Mukherjee R, Back MF, Lee KM, Lu JJ, Wynee CJ, Lim K, Tang J, Zhang X. Efficacy of an integrated continuing medical education (CME) and quality improvement (QI) program on radiation oncologist (RO) clinical practice. Int J Radiation Oncology Biology Physics 2006; 66: 1457-1460. IF 4.556.
40. Ma, X, Lu JJ, Loh KST, Shakespeare TP, Thiagarajan A, Goh BC, Tan KSL. Role of CT Imaging in Predicting Response of Nasopharyngeal Carcinoma to Definitive Radiation Therapy. Laryngoscope 2006; 116: 2162-2165. IF 1.617.
41. Tey J, Back MF, Shakespeare TP et al. The Role of Palliative Radiation Therapy in Symptomatic Locally Advanced Gastric Cancer. Int J Radiation Oncol Biology Physics 2007; 67(2): 385-8. IF 4.556.
42. Shakespeare TP, Tang JI, Shen L, Lu JJ, Mukherjee RK, Lee KM, Wynne CJ, Back MF. Does the implementation of oncology outpatient infection control measures adversely affect patient satisfaction with doctor-patient interaction? Sing Med J 2007; 48(3): 246-251.
43. Chapman A, Shakespeare T, Turner M. Improving access to radiotherapy for regional cancer patients – the National Radiotherapy Single Machine Unit Trial. Cancer Forum 2007; 31 (2): 74-76.
44. Shakespeare TP. Toohey J. Radiation Oncology Clinical Audit: A Matter of Behaviour and Performance (Letter). Austral Radiol 2007 51(3): 298-9.
45. Shakespeare TP, Turner M, Chapman A. Is Rural Radiation Oncology Practice Quality as Good as the Big Smoke? Results of the Australian Radiotherapy Single Machine Unit Trial. Austral Radiol 2007; 51(4)381-5.
46. Lee K, Tsou I, Wong S, Yu C, Ming Z, Loh Y, Shakespeare T, Mukherjee R, Back M. Metastatic spinal cord compression as an oncological emergency: getting our ACT together. Int J Qual Health Care 2007; 19(6): 377-81.
47. Lu JJ, Kong L, Shakespeare TP, Loh KS, Zhang Q, Luke Tan KS, Lee KM. Prospective phase II trial of concomitant boost radiotherapy for stage II nasopharyngeal carcinoma. Oral Oncol 2008; 44(7): 703-9
48. Shakespeare TP, Gebski V, Tang J, Lim K, Lu JJ, Zhang XJ, Jiang G. Impact of result presentation on research interpretation and medical decision-making: analysis of the PRIMER Collaboration randomized studies. Med Decis Making 2008 28(1):127-37. IF 1.822
49. Toohey J, Shakespeare TP, Morgan G. The RANZCR 2006 Peer review audit instrument. J Med Imaging Radiat Oncol. 2008; 52(4): 403-13.
50. Bell LJ, Shakespeare TP, Willis A. The importance of daily electronic portal imaging (EPI) in radiotherapy. J Med Imaging Radiat Oncol. 2008; 52(4): 414-18.
51. Tchoyoson Lim CC, Thiagarajan A, Sim CS, Khoo ML, Shakespeare TP, Ng I Craniospinal dissemination in teratocarcinosarcoma. J Neurosurg 2008; 109(2): 321-4.
52. Tang JI, Shakespeare TP, Lu JJ, Chan YH, Lee KM, Wong LC, Mukherjee RK, Back MF. Patients’ Preference for Radiotherapy Fractionation Schedule in the Palliation of Symptomatic Unresectable Lung Cancer. J Med Imag Radiat Oncol 2008; 52 (5): 497-502.
53. Leong CN, Chung HT, Lee KM, Shakespeare TP, Mukherjee RK, Wong LC, Lu JJ, Tey J, Lim R, So JB, Back MF. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma. Cancer J 2008; 14(4): 269-75.
54. Sidhom MA, Kneebone AB, Lehman M, Wiltshire KL, Millar JL, Mukherjee RK, Shakespeare TP, Tai KH. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 2008; 88(1): 10-9.
55. Aherne NJ, Steer AN, Warrier A, Shakespeare TP. Syndrome of inappropriate antidiuresis (SIAD) in a patient with rectal carcinoma undergoing preoperative radiation. Int J Colorectal Dis. 2009 Jan | |
| | |
Profile last updated: 27/03/2009 Need to update your profile? Login to your profile with your Staff ID, prefixed by a lower case "s" or "z" (eg s1234567 or z1234567), and UniPass to update your profile. If you have any problems please send an email to .
|
|